Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Allogene Therapeutics Announces Retirement of CFO Geoffrey Parker
PUBLIC · ALLOSep 02, 2026•5 days ago
Position
Executive Vice President
Company
Allogene Therapeutics, Inc.
Geoffrey Parker
San FranciscoBiotechnologyHealth CareTherapeutics
Description
On August 31, 2026, Allogene Therapeutics, Inc. announced the retirement of Geoffrey Parker, the Executive Vice President and Chief Financial Officer. His retirement will be effective on November 6, 2026
Company Information
Company
Allogene Therapeutics, Inc.
Location
270 LITTLEFIELD AVE
San Francisco, California, United States
About
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.
For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines
Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
Don't miss Allogene Therapeutics, Inc.'s next move
Get an email the moment Allogene Therapeutics, Inc. changes its leadership, hires an exec, or expands, usually minutes after it happens.
San FranciscoBiotechnologyHealth CareTherapeutics